Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
August 09, 2022 16:23 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering
August 05, 2022 09:28 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe
July 28, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements
July 15, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has...
Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study
July 06, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases,...
Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 15, 2022 16:01 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
June 15, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
May 23, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
April 25, 2022 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome
March 15, 2022 08:41 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...